Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats multiple myeloma. Sold as Empliciti. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Elotuzumab (sold as Empliciti), first approved Nov 30, 2015, with 4 new uses approved and 0 published complete response letters.
First approved: Nov 30, 2015
Applications: 1
New uses approved: 4
Complete response letters: 0
Medicare spending, 2025: $80.4M
First approved in the EU: May 11, 2016
First approved in Japan: Sep 28, 2016
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 10 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
EmplicitiDrugs with a new dosage indicated for the treatment of relapsed or refractory multiple myeloma. · Bristol-Myers Squibb K.K. · Nov 22, 2019
Empliciti, new ingredientDrugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. · Bristol-Myers Squibb Company · Sep 28, 2016 · Review report
Clinical Trials
21 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Bristol Myers Squibb